<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HB1BDD327A3124F4DABCE3344213445EF" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 6227 IH: Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-11-03</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 6227</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20231103">November 3, 2023</action-date><action-desc><sponsor name-id="S001183">Mr. Schweikert</sponsor> (for himself, <cosponsor name-id="M001165">Mr. McCarthy</cosponsor>, <cosponsor name-id="B001248">Mr. Burgess</cosponsor>, <cosponsor name-id="S001224">Mr. Self</cosponsor>, <cosponsor name-id="C001133">Mr. Ciscomani</cosponsor>, <cosponsor name-id="A000377">Mr. Armstrong</cosponsor>, <cosponsor name-id="G000574">Mr. Gallego</cosponsor>, <cosponsor name-id="C001134">Ms. Caraveo</cosponsor>, <cosponsor name-id="C001059">Mr. Costa</cosponsor>, <cosponsor name-id="G000551">Mr. Grijalva</cosponsor>, <cosponsor name-id="S001135">Mrs. Steel</cosponsor>, <cosponsor name-id="L000593">Mr. Levin</cosponsor>, <cosponsor name-id="D000594">Ms. De La Cruz</cosponsor>, and <cosponsor name-id="V000129">Mr. Valadao</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.</official-title></form><legis-body id="HA7D05906C6CB4B63ADD22B4AA29E510B" style="OLC"><section id="H693B153EA9ED407ABD4B759E40CB75A9" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023</short-title></quote>.</text></section><section id="H8590D66BD1F745B3BA115AF5A0550F49"><enum>2.</enum><header>Expanding tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis</header><text display-inline="no-display-inline">Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360n">21 U.S.C. 360n(a)(3)</external-xref>) is amendedâ€”</text><paragraph id="H82B13D14529D45D4AC907C95053CDB24"><enum>(1)</enum><text>by redesignating subparagraph (S) as subparagraph (T); and</text></paragraph><paragraph id="HD5E3D9602AEE4C86A1EBB7D59FF8046F"><enum>(2)</enum><text>by inserting after subparagraph (R) the following:</text><quoted-block style="OLC" id="H17D6CBB658B74CEE9A9D019FAEF33EB0" display-inline="no-display-inline"><subparagraph id="H1852D87434F14E318BFA4D340BECDEBA"><enum>(S)</enum><text display-inline="yes-display-inline">Coccidioidomycosis.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></legis-body></bill> 

